CARA Shares Outstanding History



Below is a table of the CARA shares outstanding history going back to 1/31/2014:

Date CARA Shares Outstanding
1/31/201421.84M
3/21/201422.59M
5/5/201422.60M
8/5/201422.64M
11/5/201422.78M
3/20/201522.82M
5/8/201522.82M
8/5/201527.16M
11/4/201527.23M
3/3/201627.25M
4/29/201627.28M
7/29/201627.28M
10/28/201627.28M
3/3/201727.30M
4/28/201732.51M
7/28/201732.58M
10/27/201732.61M
3/8/201832.69M
5/3/201832.70M
8/1/201839.29M
11/1/201839.45M
3/5/201939.55M
5/2/201939.75M
8/2/201946.42M
7/26/201920.10M
11/1/201946.68M
2/24/202046.73M
5/7/202046.80M
8/6/202046.89M
11/5/202049.83M
2/22/202149.88M
5/6/202150.05M
8/5/202150.09M
11/4/202153.46M
2/24/202253.51M
5/5/202253.59M
8/4/202253.73M
11/3/202253.73M
5/11/202353.98M
11/9/202354.48M
3/1/202454.66M

Also see: CARA Market Cap History
CARA YTD Return
CARA Historical Shares Outstanding:
+9.52% CAGR
CARA Historical Shares Outstanding: +9.52% CAGR

Mouse over chart for data details
1/31/2014 ...3/1/2024
Cara Therapeutics is an early commercial-stage biopharmaceutical company focusing on a new treatment paradigm to improve the lives of patients suffering from pruritus. Co.'s KORSUVA injection is an FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease, in adults undergoing hemodialysis. Co. is developing an Oral KORSUVA (difelikefalin) formulation for the treatment of pruritus in patients with atopic dermatitis, and non-dialysis-dependent chronic kidney disease. Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis, and in notalgia paresthetica patients with moderate-to-severe pruritus. We show 41 historical shares outstanding datapoints in our coverage of CARA's shares outstanding history.

Understanding the changing numbers of CARA shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like CARA versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching CARA by allowing them to research CARA shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree CARA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Cara Therapeutics (CARA) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

CARM Shares Outstanding History
CASI Shares Outstanding History
CASM Shares Outstanding History
CATB Shares Outstanding History
CATS Shares Outstanding History
CBAY Shares Outstanding History
CBIO Shares Outstanding History
CBLI Shares Outstanding History
CBM Shares Outstanding History
CBMG Shares Outstanding History
More Healthcare companies »

 

CARA Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.